Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Japan Tissue Engineering Co., Ltd. ( (JP:7774) ) has provided an update.
Japan Tissue Engineering reported non-consolidated results for the nine months to 31 December 2025 showing an 11.5% year-on-year decline in net sales to ¥1.51 billion and a deeper operating loss of ¥563 million, with net loss widening to ¥556 million as earnings per share fell to negative ¥13.70. Total assets decreased to ¥5.89 billion and equity declined, though the equity ratio remained high at 89.4%, the company maintained a zero-dividend policy for the period and full year, and it revised its full-year forecast to project a 10% drop in sales to ¥2.21 billion and a continued net loss of ¥540 million, underscoring ongoing profitability challenges despite a still-solid capital base.
The most recent analyst rating on (JP:7774) stock is a Hold with a Yen578.00 price target. To see the full list of analyst forecasts on Japan Tissue Engineering Co., Ltd. stock, see the JP:7774 Stock Forecast page.
More about Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. is a Japanese company listed on the Tokyo Stock Exchange that operates in the regenerative medicine and tissue engineering field, developing and supplying cell- and tissue-based medical products. Its business focuses on niche, high-value healthcare segments, where long development cycles and reimbursement conditions can lead to volatile revenues and earnings.
Average Trading Volume: 194,474
Technical Sentiment Signal: Buy
Current Market Cap: Yen23.35B
For a thorough assessment of 7774 stock, go to TipRanks’ Stock Analysis page.